Human Molecular Genetics Advance Access originally published online on January 13, 2005
Human Molecular Genetics 2005 14(4):555-563; doi:10.1093/hmg/ddi052
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human Molecular Genetics, Vol. 14, No. 4 © Oxford University Press 2005; all rights reserved
Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population
1Departments of Medicine (Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA 98195-7720, USA, 2Shaare Zedek Medical Center, Hebrew University, Jerusalem 91031, Israel and 3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Received November 22, 2004; Accepted December 30, 2004
Functional and genomic approaches can be integrated to screen efficiently for pathogenic alleles in founder populations. We applied such approaches to analysis of the cancer-associated cell cycle regulator CHEK2 in the Ashkenazi Jewish population. We first identified two extended haplotypes at CHEK2 that co-segregated with breast cancer in high-risk families. We sequenced CHEK2 in a case representing each haplotype and discovered two novel amino acid substitutions, CHEK2.S428F in the kinase domain and CHEK2.P85L in the N-terminal region. To assay these alleles for loss of CHEK2 function, we tested their capacity to complement Rad53 deletion in Saccharomyces cerevisiae. CHEK2.S428F failed to complement Rad53 and thus largely abrogates normal CHEK2 function, whereas CHEK2.P85L complemented Rad53 as well as did wild-type CHEK2. Epidemiologic analyses were concordant with the functional tests. Frequencies of CHEK2.S428F heterozygotes were 2.88% (47/1632) among female breast cancer patients not selected for family history or age at diagnosis and 1.37% (23/1673) among controls (OR=2.13, 95% CI [1.26, 3.69], P=0.004), whereas frequencies of CHEK2.P85L were 0.92% among cases and 0.83% among controls. On the basis of the experience of mothers, sisters and daughters of probands, breast cancer risk due to CHEK2.S428F was estimated as 0.17 (±0.08) by age 60. We conclude that CHEK2.S428F increases breast cancer risk
2-fold among Ashkenazi Jewish women, whereas CHEK2.P85L is a neutral allele. In general, these results suggest that selecting probands with extended haplotypes that co-segregate with disease can improve the efficiency of resequencing efforts and that quantitative complementation tests in yeast can be used to evaluate variants in genes with highly conserved function.
* To whom correspondence should be addressed. Email: mcking{at}u.washington.edu
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. Kirchhoff, Z.-q. Chen, B. Gold, P. Pal, M. M. Gaudet, K. Kosarin, D. A. Levine, P. Gregersen, S. Spencer, M. Harlan, et al. The 6q22.33 Locus and Breast Cancer Susceptibility Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2468 - 2475. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Sehl, L. R. Langer, J. C. Papp, L. Kwan, J. L. Seldon, G. Arellano, J. Reiss, E. F. Reed, S. Dandekar, Y. Korin, et al. Associations between Single Nucleotide Polymorphisms in Double-Stranded DNA Repair Pathway Genes and Familial Breast Cancer Clin. Cancer Res., March 15, 2009; 15(6): 2192 - 2203. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zhang, C. M. Phelan, P. Zhang, F. Rousseau, P. Ghadirian, A. Robidoux, W. Foulkes, N. Hamel, D. McCready, M. Trudeau, et al. Frequency of the CHEK2 1100delC Mutation among Women with Breast Cancer: An International Study Cancer Res., April 1, 2008; 68(7): 2154 - 2157. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Offit and J. E. Garber Time to Check CHEK2 in Families With Breast Cancer? J. Clin. Oncol., February 1, 2008; 26(4): 519 - 520. [Full Text] [PDF] |
||||
![]() |
C Cybulski, D Wokolorczyk, T Huzarski, T Byrski, J Gronwald, B Gorski, T Debniak, B Masojc, A Jakubowska, B Gliniewicz, et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer J. Med. Genet., November 1, 2006; 43(11): 863 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cybulski, B. Gorski, T. Huzarski, T. Byrski, J. Gronwald, T. Debniak, D. Wokolorczyk, A. Jakubowska, E. Kowalska, O. Oszurek, et al. CHEK2-Positive Breast Cancers in Young Polish Women. Clin. Cancer Res., August 15, 2006; 12(16): 4832 - 4835. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Walsh, S. Casadei, K. H. Coats, E. Swisher, S. M. Stray, J. Higgins, K. C. Roach, J. Mandell, M. K. Lee, S. Ciernikova, et al. Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer JAMA, March 22, 2006; 295(12): 1379 - 1388. [Abstract] [Full Text] [PDF] |
||||





